Table 2.
Ongoing adjuvant trials
| Study | No. of patients | TNM stage | Therapy | Primary endpoint |
|---|---|---|---|---|
| US Intergroup E1609 | 1600 | III (IIIB–c), IV (M1a, M1b) | Ipilimumab 3 mg/kg or 10 g/kg vs HD-IFN | RFS, OS |
| COMBI-AD | 852 | III (BRAF V600E/K) | Dabrafenib + trametinib vs. placebo | RFS |
| BRIM-8 | 725 | IIC, III (BRAF V600; Cobas) | Vemurafenib vs. placebo | DFS |
| EORTC-1325/KEYNOTE-054 | 900 | IIA (> 1 mm met), IIIb–C | Pembrolizumab vs. placebo | RFS, RFS in PDL1+ |
| CheckMate-238 | 800 | IIIB–C, IV | Nivolumab vs. ipilimumab 10 g/kg | RFS |
| US Intergroup S1404 | 1240 | IIIA (N2), IIIB–C, M | Pembrolizumab vs. HD-IFN or ipilimumab 10 mg/kg | RFS, OS |
| C heckMate-915 | 1125 | IIIB–D, IV | Ipilimumab + nivolumab vs ipilimumab or nivolumab | RFS |